EPE Special Opps Ltd - Trading Update
Announcement provided by
EPE Special Opportunities Ltd · EO.P06/02/2023 07:00

EPE Special Opportunities Limited
("ESO" or the "Company")
Trading Statement
The Board of EPE Special Opportunities is pleased to provide an update on the Company's performance for the year ended 31 January 2023.
Summary
· The Company's performance in the year ended 31 January 2023 has been affected by adverse macro-economic conditions and a recessionary environment. The Board and Investment Advisor expect these headwinds to continue through the immediate period but look forward to the normalisation of trading conditions over the medium term. Notwithstanding these headwinds, the Company was pleased to announce the completion of a new investment in Denzel's Limited ("Denzel's") in October 2022. Looking ahead, the Board and Investment Advisor will continue to adopt a careful approach, monitoring economic conditions, maintaining a prudent level of liquidity at the Company and positioning the portfolio to navigate the complicated operating environment. As a result of the uncertainty on market outlook, the Board expects a challenging environment to complete further acquisitions or disposals within the portfolio in the near term.
· The unaudited estimate of the Net Asset Value ("NAV") per share of the Company as at 31 January 2023 was
· The share price of the Company as at 31 January 2023 was
· In January 2023, Luceco released a trading update for the year ended 31 December 2022, announcing trading in line with market expectations. The group announced sales of
· The Rayware Group's ("Rayware") trading has been impacted by a confluence of challenges, including customer destocking, decreased consumer confidence and supply chain disruption. The business expects performance to strengthen over the coming period, benefitting from abating input cost, supply chain and customer destocking pressures. The business has continued to develop its presence in international markets, and has appointed Alec Taylor, former director of Bradshaw International, as a non-executive director and made a number of additions to the US sales team to support the strategic focus on the US market.
· Whittard of
· David Phillips made good progress, despite the wider inflationary environment, generating strong cash generation in the period. The business is focussed on achieving further growth in its existing channels and accessing greater profitability through efficiencies and scale.
· Pharmacy2U has continued to experience growth in its core NHS online prescription channel and has been focussed on building scale in its primary Bardon facility to increase operational efficiency.
· EPIC Acquisition Corp ("EAC") has progressed to advanced discussions with a number of European consumer brands regarding a potential business combination. EAC continues to actively source and review a pipeline of attractive targets.
· In October 2022, the Company announced a
· The Company's investments in Atlantic Credit Opportunities Fund and Prelude Structured Alternatives Master Fund are in the process of realisation, with the distribution of proceeds to the Company to be completed in the coming period.
· The Company had cash balances of
· In September and October 2022, the Company completed buybacks in the market totalling 1.9 million ordinary shares (or 5.4 per cent. of the Company's issued ordinary share capital) at a weighted average share price of
· As at 31 January 2023, the Company's unquoted portfolio was valued at a weighted average EBITDA to enterprise value multiple of 6.7x (excluding assets investing for growth) and the portfolio had a low level of third party leverage with net debt at 1.3x EBITDA in aggregate.
Mr Clive Spears, Chairman, commented: "The Company has faced significant macro-economic headwinds in the period, but the Board and Investment Advisor have maintained a careful approach, positioning the portfolio and the Company accordingly. The Company was pleased to announce the completion of the new investment in Denzel's and continues to review a pipeline of attractive investments. The Board would like to note its appreciation of the Investment Advisor and the portfolio management teams for their efforts through a complicated period. The Board will monitor the progress of the portfolio over the coming months and looks forward to updating shareholders at the half year."
The person responsible for releasing this information on behalf of the Company is Amanda Robinson of Langham Hall Fund Management (Jersey) Limited.
Enquiries:
EPIC Investment Partners LLP |
+44 (0) 207 269 8865 Alex Leslie |
Langham Hall Fund Management (Jersey) Limited |
+44 (0) 15 3488 5200 Amanda Robinson |
Cardew Group Limited |
+44 (0) 207 930 0777 Richard Spiegelberg |
Numis Securities Limited |
+44 (0) 207 260 1000 |
Nominated Advisor: |
Stuart Skinner |
Corporate Broker: |
Charles Farquhar |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.